Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 390 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Psychosis NOS Clear all
Completed Not applicable Interventional Results available

rTMS in First Episode Psychosis

NCT02131129
View directory record Official record
Conditions
Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
Interventions
rTMS, Sham Comparator
Device
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Racial Disparities in the Expression of Paranoia

NCT07460453
View directory record Official record
Conditions
Paranoia, Psychotic Disorders
Interventions
Guided Visual Imagery Task
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional

Schizophrenia Study In Adults

NCT00049946
View directory record Official record
Conditions
Schizophrenia
Interventions
talnetant, risperidone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
31
States / cities
Scottsdale, Arizona • Cerritos, California • Chula Vista, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2017 · Synced Oct 22, 2026, 5:03 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

NCT00637494
View directory record Official record
Conditions
Psychotic Depression, Severe Major Depression With Psychotic Features, Psychosis
Interventions
mifepristone, placebo
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
22 Years and older
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
42
States / cities
Little Rock, Arkansas • Anaheim, California • Downey, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional Results available

Facilitating Engagement in Evidence-Based Treatment for Early Psychosis

NCT04532034
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Peer-Delivered Decision Support Intervention
Behavioral
Lead sponsor
Temple University
Other
Eligibility
18 Years to 30 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Broomall, Pennsylvania • Danville, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Early Phase 1 Interventional

Effects Zulresso on Postpartum Psychosis

NCT05314153
View directory record Official record
Conditions
Postpartum Psychosis
Interventions
Brexanolone
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 26, 2024 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 3 Interventional

Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis

NCT07095465
View directory record Official record
Conditions
Lewy Body Dementia Psychosis
Interventions
ACP-204
Drug
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Eligibility
55 Years to 84 Years
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
18
States / cities
Irvine, California • Aventura, Florida • Boca Raton, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 4 Interventional Results available

Prevention of N-methyl-D-aspartate (NMDA) Antagonist-induced Psychosis in Kids

NCT00205712
View directory record Official record
Conditions
Psychoses, Substance-Induced
Interventions
Ketamine, Dexmedetomidine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
7 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Academic-Community EPINET (AC-EPINET)

NCT04497857
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorders, Major Depression With Psychotic Features, Bipolar Disorder With Psychotic Features
Interventions
Coordinated Specialty Care (CSC)
Other
Lead sponsor
Indiana University
Other
Eligibility
16 Years to 35 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
6
States / cities
Indianapolis, Indiana • New Orleans, Louisiana • Ann Arbor, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

FAAH Availability in Psychiatric Disorders: A PET Study

NCT04404712
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Alcohol Use Disorder, Psychosis
Interventions
[11C]MK-3168
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 1 Interventional

Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics

NCT00628420
View directory record Official record
Conditions
Schizophrenia
Interventions
ACP-104, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2011 · Synced Oct 22, 2026, 5:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Longitudinal Multimodal Neuroimaging Studies in Patients With First Episode Psychosis

NCT01688765
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Observational
Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2022
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Improving Care and Reducing Cost Study

NCT02364544
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Psychosis NOS
Interventions
Relapse Prevention Plan, Daily Support Website, Computer CBT for voices and paranoia, FOCUS, Prescriber Decision Assistant
Behavioral · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
461 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
8
States / cities
Fort Lauderdale, Florida • Lawrenceburg, Indiana • Grand Rapids, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Not applicable Interventional

The Effectiveness of Individualized Imagery Scripts on Sleep, Psychosis, and Suicidality Among Inpatients With Psychosis

NCT06194344
View directory record Official record
Conditions
Psychosis
Interventions
Individualized imagery, Control
Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Smoking Cessation for Veterans With Severe and Persistent Mental Illness

NCT00960375
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia, Affective Psychosis, Bipolar, Affective Disorders, Psychotic
Interventions
BTSCS, StSST
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 75 Years
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2015 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 4 Interventional

Exercise and Olanzapine-samidorphan

NCT06740890
View directory record Official record
Conditions
Schizophenia Disorder, Schizoaffective Disorder, Bipolar Disorder I or II, Bipolar Disorder NOS
Interventions
Olanzapine-samidorphan + exercise
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 22, 2026, 5:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Psychiatric and Cognitive Manifestations of Parkinson's Disease

NCT00360633
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 22, 2026, 5:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Neurophysiological Studies in Schizophrenia and Psychiatric Disorders

NCT01384604
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
15 Years to 70 Years
Enrollment
1,189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional

Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis

NCT02566057
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders, Bipolar Disorder
Interventions
PGx testing guided treatment (PGT)
Biological
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

NCT02634684
View directory record Official record
Conditions
Schizophrenia
Interventions
Dextroamphetamine, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2021 · Synced Oct 22, 2026, 5:03 PM EDT
Completed No phase listed Observational

Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment

NCT01364818
View directory record Official record
Conditions
Autism Spectrum Disorders, Psychosis, Fragile X Syndrome
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
3 Years to 45 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 18, 2016 · Synced Oct 22, 2026, 5:03 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

NCT05890768
View directory record Official record
Conditions
Psychosis
Interventions
Lumateperone, Risperidone
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 22, 2026, 5:03 PM EDT
Completed Not applicable Interventional Results available

Mobile After-Care Support App: Pilot RCT

NCT03955250
View directory record Official record
Conditions
Psychotic Disorder
Interventions
Mobile After-Care Support (MACS) app, Mobile app attention control
Behavioral
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 22, 2026, 5:03 PM EDT
Recruiting Phase 3 Interventional

Effects of Cannabidiol (CBD) Versus Placebo as an Adjunct to Treatment in Early Psychosis

NCT04411225
View directory record Official record
Conditions
Early Psychosis
Interventions
Cannabidiol oral solution
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
16 Years to 30 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
La Jolla, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 22, 2026, 5:03 PM EDT